0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Metabolic Disease Drug Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-33K12899
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global Chronic Metabolic Disease Drug Market Research Report 2023
BUY CHAPTERS

Global Chronic Metabolic Disease Drug Market Research Report 2025

Code: QYRE-Auto-33K12899
Report
May 2025
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Chronic Metabolic Disease Drug Market Size

The global market for Chronic Metabolic Disease Drug was valued at US$ 57350 million in the year 2024 and is projected to reach a revised size of US$ 95090 million by 2031, growing at a CAGR of 7.6% during the forecast period.

Chronic Metabolic Disease Drug Market

Chronic Metabolic Disease Drug Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chronic Metabolic Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Metabolic Disease Drug.
The Chronic Metabolic Disease Drug market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Metabolic Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Metabolic Disease Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Chronic Metabolic Disease Drug Market Report

Report Metric Details
Report Name Chronic Metabolic Disease Drug Market
Accounted market size in year US$ 57350 million
Forecasted market size in 2031 US$ 95090 million
CAGR 7.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Daiichi Sankyo, Actelion Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Fresenius Kabi, Torrent Labs, Pfizer, Novo Nordisk, AstraZeneca plc, Regeneron Pharmaceuticals, GlaxoSmithKline plc, Merck & Co. Inc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Chronic Metabolic Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Chronic Metabolic Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Chronic Metabolic Disease Drug Market growing?

Ans: The Chronic Metabolic Disease Drug Market witnessing a CAGR of 7.6% during the forecast period 2025-2031.

What is the Chronic Metabolic Disease Drug Market size in 2031?

Ans: The Chronic Metabolic Disease Drug Market size in 2031 will be US$ 95090 million.

Who are the main players in the Chronic Metabolic Disease Drug Market report?

Ans: The main players in the Chronic Metabolic Disease Drug Market are Novartis, Daiichi Sankyo, Actelion Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Fresenius Kabi, Torrent Labs, Pfizer, Novo Nordisk, AstraZeneca plc, Regeneron Pharmaceuticals, GlaxoSmithKline plc, Merck & Co. Inc

What are the Application segmentation covered in the Chronic Metabolic Disease Drug Market report?

Ans: The Applications covered in the Chronic Metabolic Disease Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Chronic Metabolic Disease Drug Market report?

Ans: The Types covered in the Chronic Metabolic Disease Drug Market report are Hypertension Drug, Hyperlipidemia Drug, High Blood Sugar Drug, High Uric Acid Drug

Recommended Reports

Metabolic Disease Drugs

Neurodegenerative Diseases

Other Chronic Disorders

1 Chronic Metabolic Disease Drug Market Overview
1.1 Product Definition
1.2 Chronic Metabolic Disease Drug by Type
1.2.1 Global Chronic Metabolic Disease Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Hypertension Drug
1.2.3 Hyperlipidemia Drug
1.2.4 High Blood Sugar Drug
1.2.5 High Uric Acid Drug
1.3 Chronic Metabolic Disease Drug by Application
1.3.1 Global Chronic Metabolic Disease Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Chronic Metabolic Disease Drug Market Size Estimates and Forecasts
1.4.1 Global Chronic Metabolic Disease Drug Revenue 2020-2031
1.4.2 Global Chronic Metabolic Disease Drug Sales 2020-2031
1.4.3 Global Chronic Metabolic Disease Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Chronic Metabolic Disease Drug Market Competition by Manufacturers
2.1 Global Chronic Metabolic Disease Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Chronic Metabolic Disease Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Chronic Metabolic Disease Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Chronic Metabolic Disease Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Chronic Metabolic Disease Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chronic Metabolic Disease Drug, Product Type & Application
2.7 Global Key Manufacturers of Chronic Metabolic Disease Drug, Date of Enter into This Industry
2.8 Global Chronic Metabolic Disease Drug Market Competitive Situation and Trends
2.8.1 Global Chronic Metabolic Disease Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Chronic Metabolic Disease Drug Players Market Share by Revenue
2.8.3 Global Chronic Metabolic Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Chronic Metabolic Disease Drug Market Scenario by Region
3.1 Global Chronic Metabolic Disease Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Chronic Metabolic Disease Drug Sales by Region: 2020-2031
3.2.1 Global Chronic Metabolic Disease Drug Sales by Region: 2020-2025
3.2.2 Global Chronic Metabolic Disease Drug Sales by Region: 2026-2031
3.3 Global Chronic Metabolic Disease Drug Revenue by Region: 2020-2031
3.3.1 Global Chronic Metabolic Disease Drug Revenue by Region: 2020-2025
3.3.2 Global Chronic Metabolic Disease Drug Revenue by Region: 2026-2031
3.4 North America Chronic Metabolic Disease Drug Market Facts & Figures by Country
3.4.1 North America Chronic Metabolic Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Chronic Metabolic Disease Drug Sales by Country (2020-2031)
3.4.3 North America Chronic Metabolic Disease Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Chronic Metabolic Disease Drug Market Facts & Figures by Country
3.5.1 Europe Chronic Metabolic Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Chronic Metabolic Disease Drug Sales by Country (2020-2031)
3.5.3 Europe Chronic Metabolic Disease Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Chronic Metabolic Disease Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Chronic Metabolic Disease Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Chronic Metabolic Disease Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Chronic Metabolic Disease Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Chronic Metabolic Disease Drug Market Facts & Figures by Country
3.7.1 Latin America Chronic Metabolic Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Chronic Metabolic Disease Drug Sales by Country (2020-2031)
3.7.3 Latin America Chronic Metabolic Disease Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Chronic Metabolic Disease Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Chronic Metabolic Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chronic Metabolic Disease Drug Sales by Type (2020-2031)
4.1.1 Global Chronic Metabolic Disease Drug Sales by Type (2020-2025)
4.1.2 Global Chronic Metabolic Disease Drug Sales by Type (2026-2031)
4.1.3 Global Chronic Metabolic Disease Drug Sales Market Share by Type (2020-2031)
4.2 Global Chronic Metabolic Disease Drug Revenue by Type (2020-2031)
4.2.1 Global Chronic Metabolic Disease Drug Revenue by Type (2020-2025)
4.2.2 Global Chronic Metabolic Disease Drug Revenue by Type (2026-2031)
4.2.3 Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2020-2031)
4.3 Global Chronic Metabolic Disease Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Chronic Metabolic Disease Drug Sales by Application (2020-2031)
5.1.1 Global Chronic Metabolic Disease Drug Sales by Application (2020-2025)
5.1.2 Global Chronic Metabolic Disease Drug Sales by Application (2026-2031)
5.1.3 Global Chronic Metabolic Disease Drug Sales Market Share by Application (2020-2031)
5.2 Global Chronic Metabolic Disease Drug Revenue by Application (2020-2031)
5.2.1 Global Chronic Metabolic Disease Drug Revenue by Application (2020-2025)
5.2.2 Global Chronic Metabolic Disease Drug Revenue by Application (2026-2031)
5.2.3 Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2020-2031)
5.3 Global Chronic Metabolic Disease Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis Chronic Metabolic Disease Drug Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Daiichi Sankyo
6.2.1 Daiichi Sankyo Company Information
6.2.2 Daiichi Sankyo Description and Business Overview
6.2.3 Daiichi Sankyo Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Daiichi Sankyo Chronic Metabolic Disease Drug Product Portfolio
6.2.5 Daiichi Sankyo Recent Developments/Updates
6.3 Actelion Pharmaceuticals
6.3.1 Actelion Pharmaceuticals Company Information
6.3.2 Actelion Pharmaceuticals Description and Business Overview
6.3.3 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
6.3.5 Actelion Pharmaceuticals Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Company Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Boehringer Ingelheim Chronic Metabolic Disease Drug Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Eli Lilly Chronic Metabolic Disease Drug Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Fresenius Kabi
6.6.1 Fresenius Kabi Company Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Fresenius Kabi Chronic Metabolic Disease Drug Product Portfolio
6.6.5 Fresenius Kabi Recent Developments/Updates
6.7 Torrent Labs
6.7.1 Torrent Labs Company Information
6.7.2 Torrent Labs Description and Business Overview
6.7.3 Torrent Labs Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Torrent Labs Chronic Metabolic Disease Drug Product Portfolio
6.7.5 Torrent Labs Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Pfizer Chronic Metabolic Disease Drug Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Novo Nordisk
6.9.1 Novo Nordisk Company Information
6.9.2 Novo Nordisk Description and Business Overview
6.9.3 Novo Nordisk Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Novo Nordisk Chronic Metabolic Disease Drug Product Portfolio
6.9.5 Novo Nordisk Recent Developments/Updates
6.10 AstraZeneca plc
6.10.1 AstraZeneca plc Company Information
6.10.2 AstraZeneca plc Description and Business Overview
6.10.3 AstraZeneca plc Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 AstraZeneca plc Chronic Metabolic Disease Drug Product Portfolio
6.10.5 AstraZeneca plc Recent Developments/Updates
6.11 Regeneron Pharmaceuticals
6.11.1 Regeneron Pharmaceuticals Company Information
6.11.2 Regeneron Pharmaceuticals Description and Business Overview
6.11.3 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
6.11.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.12 GlaxoSmithKline plc
6.12.1 GlaxoSmithKline plc Company Information
6.12.2 GlaxoSmithKline plc Description and Business Overview
6.12.3 GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 GlaxoSmithKline plc Chronic Metabolic Disease Drug Product Portfolio
6.12.5 GlaxoSmithKline plc Recent Developments/Updates
6.13 Merck & Co. Inc
6.13.1 Merck & Co. Inc Company Information
6.13.2 Merck & Co. Inc Description and Business Overview
6.13.3 Merck & Co. Inc Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Merck & Co. Inc Chronic Metabolic Disease Drug Product Portfolio
6.13.5 Merck & Co. Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chronic Metabolic Disease Drug Industry Chain Analysis
7.2 Chronic Metabolic Disease Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chronic Metabolic Disease Drug Production Mode & Process Analysis
7.4 Chronic Metabolic Disease Drug Sales and Marketing
7.4.1 Chronic Metabolic Disease Drug Sales Channels
7.4.2 Chronic Metabolic Disease Drug Distributors
7.5 Chronic Metabolic Disease Drug Customer Analysis
8 Chronic Metabolic Disease Drug Market Dynamics
8.1 Chronic Metabolic Disease Drug Industry Trends
8.2 Chronic Metabolic Disease Drug Market Drivers
8.3 Chronic Metabolic Disease Drug Market Challenges
8.4 Chronic Metabolic Disease Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Chronic Metabolic Disease Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Chronic Metabolic Disease Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Chronic Metabolic Disease Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Chronic Metabolic Disease Drug Sales (Tons) of Key Manufacturers (2020-2025)
 Table 5. Global Chronic Metabolic Disease Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Chronic Metabolic Disease Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Chronic Metabolic Disease Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Chronic Metabolic Disease Drug Average Price (US$/Ton) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Chronic Metabolic Disease Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Chronic Metabolic Disease Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Chronic Metabolic Disease Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Chronic Metabolic Disease Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Chronic Metabolic Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Metabolic Disease Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Chronic Metabolic Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Chronic Metabolic Disease Drug Sales by Region (2020-2025) & (Tons)
 Table 18. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Chronic Metabolic Disease Drug Sales by Region (2026-2031) & (Tons)
 Table 20. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Chronic Metabolic Disease Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Chronic Metabolic Disease Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Chronic Metabolic Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Chronic Metabolic Disease Drug Sales by Country (2020-2025) & (Tons)
 Table 27. North America Chronic Metabolic Disease Drug Sales by Country (2026-2031) & (Tons)
 Table 28. North America Chronic Metabolic Disease Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Chronic Metabolic Disease Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Chronic Metabolic Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Chronic Metabolic Disease Drug Sales by Country (2020-2025) & (Tons)
 Table 32. Europe Chronic Metabolic Disease Drug Sales by Country (2026-2031) & (Tons)
 Table 33. Europe Chronic Metabolic Disease Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Chronic Metabolic Disease Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Chronic Metabolic Disease Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Chronic Metabolic Disease Drug Sales by Region (2020-2025) & (Tons)
 Table 37. Asia Pacific Chronic Metabolic Disease Drug Sales by Region (2026-2031) & (Tons)
 Table 38. Asia Pacific Chronic Metabolic Disease Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Chronic Metabolic Disease Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Chronic Metabolic Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Chronic Metabolic Disease Drug Sales by Country (2020-2025) & (Tons)
 Table 42. Latin America Chronic Metabolic Disease Drug Sales by Country (2026-2031) & (Tons)
 Table 43. Latin America Chronic Metabolic Disease Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Chronic Metabolic Disease Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2020-2025) & (Tons)
 Table 47. Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2026-2031) & (Tons)
 Table 48. Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Chronic Metabolic Disease Drug Sales (Tons) by Type (2020-2025)
 Table 51. Global Chronic Metabolic Disease Drug Sales (Tons) by Type (2026-2031)
 Table 52. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Chronic Metabolic Disease Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Chronic Metabolic Disease Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Chronic Metabolic Disease Drug Price (US$/Ton) by Type (2020-2025)
 Table 59. Global Chronic Metabolic Disease Drug Price (US$/Ton) by Type (2026-2031)
 Table 60. Global Chronic Metabolic Disease Drug Sales (Tons) by Application (2020-2025)
 Table 61. Global Chronic Metabolic Disease Drug Sales (Tons) by Application (2026-2031)
 Table 62. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Chronic Metabolic Disease Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Chronic Metabolic Disease Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Chronic Metabolic Disease Drug Price (US$/Ton) by Application (2020-2025)
 Table 69. Global Chronic Metabolic Disease Drug Price (US$/Ton) by Application (2026-2031)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 73. Novartis Chronic Metabolic Disease Drug Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Daiichi Sankyo Company Information
 Table 76. Daiichi Sankyo Description and Business Overview
 Table 77. Daiichi Sankyo Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 78. Daiichi Sankyo Chronic Metabolic Disease Drug Product
 Table 79. Daiichi Sankyo Recent Developments/Updates
 Table 80. Actelion Pharmaceuticals Company Information
 Table 81. Actelion Pharmaceuticals Description and Business Overview
 Table 82. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 83. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product
 Table 84. Actelion Pharmaceuticals Recent Developments/Updates
 Table 85. Boehringer Ingelheim Company Information
 Table 86. Boehringer Ingelheim Description and Business Overview
 Table 87. Boehringer Ingelheim Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 88. Boehringer Ingelheim Chronic Metabolic Disease Drug Product
 Table 89. Boehringer Ingelheim Recent Developments/Updates
 Table 90. Eli Lilly Company Information
 Table 91. Eli Lilly Description and Business Overview
 Table 92. Eli Lilly Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 93. Eli Lilly Chronic Metabolic Disease Drug Product
 Table 94. Eli Lilly Recent Developments/Updates
 Table 95. Fresenius Kabi Company Information
 Table 96. Fresenius Kabi Description and Business Overview
 Table 97. Fresenius Kabi Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 98. Fresenius Kabi Chronic Metabolic Disease Drug Product
 Table 99. Fresenius Kabi Recent Developments/Updates
 Table 100. Torrent Labs Company Information
 Table 101. Torrent Labs Description and Business Overview
 Table 102. Torrent Labs Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 103. Torrent Labs Chronic Metabolic Disease Drug Product
 Table 104. Torrent Labs Recent Developments/Updates
 Table 105. Pfizer Company Information
 Table 106. Pfizer Description and Business Overview
 Table 107. Pfizer Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 108. Pfizer Chronic Metabolic Disease Drug Product
 Table 109. Pfizer Recent Developments/Updates
 Table 110. Novo Nordisk Company Information
 Table 111. Novo Nordisk Description and Business Overview
 Table 112. Novo Nordisk Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 113. Novo Nordisk Chronic Metabolic Disease Drug Product
 Table 114. Novo Nordisk Recent Developments/Updates
 Table 115. AstraZeneca plc Company Information
 Table 116. AstraZeneca plc Description and Business Overview
 Table 117. AstraZeneca plc Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 118. AstraZeneca plc Chronic Metabolic Disease Drug Product
 Table 119. AstraZeneca plc Recent Developments/Updates
 Table 120. Regeneron Pharmaceuticals Company Information
 Table 121. Regeneron Pharmaceuticals Description and Business Overview
 Table 122. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 123. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product
 Table 124. Regeneron Pharmaceuticals Recent Developments/Updates
 Table 125. GlaxoSmithKline plc Company Information
 Table 126. GlaxoSmithKline plc Description and Business Overview
 Table 127. GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 128. GlaxoSmithKline plc Chronic Metabolic Disease Drug Product
 Table 129. GlaxoSmithKline plc Recent Developments/Updates
 Table 130. Merck & Co. Inc Company Information
 Table 131. Merck & Co. Inc Description and Business Overview
 Table 132. Merck & Co. Inc Chronic Metabolic Disease Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 133. Merck & Co. Inc Chronic Metabolic Disease Drug Product
 Table 134. Merck & Co. Inc Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Chronic Metabolic Disease Drug Distributors List
 Table 138. Chronic Metabolic Disease Drug Customers List
 Table 139. Chronic Metabolic Disease Drug Market Trends
 Table 140. Chronic Metabolic Disease Drug Market Drivers
 Table 141. Chronic Metabolic Disease Drug Market Challenges
 Table 142. Chronic Metabolic Disease Drug Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Chronic Metabolic Disease Drug
 Figure 2. Global Chronic Metabolic Disease Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Chronic Metabolic Disease Drug Market Share by Type: 2024 & 2031
 Figure 4. Hypertension Drug Product Picture
 Figure 5. Hyperlipidemia Drug Product Picture
 Figure 6. High Blood Sugar Drug Product Picture
 Figure 7. High Uric Acid Drug Product Picture
 Figure 8. Global Chronic Metabolic Disease Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Chronic Metabolic Disease Drug Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Others
 Figure 13. Global Chronic Metabolic Disease Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Chronic Metabolic Disease Drug Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Chronic Metabolic Disease Drug Sales (2020-2031) & (Tons)
 Figure 16. Global Chronic Metabolic Disease Drug Average Price (US$/Ton) & (2020-2031)
 Figure 17. Chronic Metabolic Disease Drug Report Years Considered
 Figure 18. Chronic Metabolic Disease Drug Sales Share by Manufacturers in 2024
 Figure 19. Global Chronic Metabolic Disease Drug Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Chronic Metabolic Disease Drug Players: Market Share by Revenue in Chronic Metabolic Disease Drug in 2024
 Figure 21. Chronic Metabolic Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Chronic Metabolic Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Chronic Metabolic Disease Drug Sales Market Share by Country (2020-2031)
 Figure 24. North America Chronic Metabolic Disease Drug Revenue Market Share by Country (2020-2031)
 Figure 25. United States Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Chronic Metabolic Disease Drug Sales Market Share by Country (2020-2031)
 Figure 28. Europe Chronic Metabolic Disease Drug Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Chronic Metabolic Disease Drug Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Chronic Metabolic Disease Drug Revenue Market Share by Region (2020-2031)
 Figure 36. China Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Chronic Metabolic Disease Drug Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Chronic Metabolic Disease Drug Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Chronic Metabolic Disease Drug Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Chronic Metabolic Disease Drug Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Chronic Metabolic Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Chronic Metabolic Disease Drug by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Chronic Metabolic Disease Drug by Type (2020-2031)
 Figure 55. Global Chronic Metabolic Disease Drug Price (US$/Ton) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Chronic Metabolic Disease Drug by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Chronic Metabolic Disease Drug by Application (2020-2031)
 Figure 58. Global Chronic Metabolic Disease Drug Price (US$/Ton) by Application (2020-2031)
 Figure 59. Chronic Metabolic Disease Drug Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

RELATED REPORTS

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33W11115
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Liraglutide Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-11A9578
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Diabetes Care Products Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I8272
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Thyroid Gland Disorder Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-16N11302
Mon Sep 08 00:00:00 UTC 2025

Add to Cart